Cancer Incidence and Mortality in the Czech Republic

Abstract

Background: The Czech Republic ranks among the countries with the highest cancer burden in Europe as well as worldwide. The purpose of this study is to summarize long-term trends in the cancer burden and to provide up-to-date estimates of incidence and mortality rates after 2011. Data and Methods: The Czech National Cancer Registry (CNCR) was instituted in 1977 and contains information collected over a 34-year period of standardized registration covering 100% of cancer dia gnoses within the entire Czech population. The CNCR analysis is supported by demographic data and by the Death Records Database. An overview of the epidemiology of malignant tumors in the Czech population is available on-line at www.svod.cz. Results: All neoplasms, including non-melanoma skin cancer, reached a crude incidence rate of almost 802 cases per 100,000 men and 681 cases per 100,000 women in 2011. The annual mortality rate exceeded 258 deaths per 100,000 individuals; in other words, more than 27,000 individuals die of cancer each year. The overall incidence of malignancies has increased with a growth index of +27.6% during the last decade (2001-2011), while the mortality rate has been stabilized over the time span (growth index in 2001-2011:-5.0%). Consequently, the prevalence has signifi cantly increased in the observed period and exceeded 475,000 cases in 2011. In addition to demographic aging of the Czech population, the cancer burden has also increased due to the growing incidence of multiple primary tumors (recently more than 15% of the total incidence). The most frequent dia gnoses include colorectal cancer, lung cancer, breast cancer, and prostate cancer. Although some neoplasms are increasingly dia gnosed at an early stage (e. g. the proportion of stage I or II was 75.3% for female breast cancer and 84.2% for skin melanoma), the numbers of early dia gnosed cases are generally insuffi cient, even in the case of highly prevalent cancers such as colorectal carcinoma (only 46.1% of incident cases are dia gnosed at stage I or II, according to recent data). Conclusion: Population-based data on malignant tumors are available in the Czech Republic. The data survey can help us defi ne national cancer management priorities. The current priority is to achieve a sustained reduction of cases dia gnosed at an advanced stage and reduction of the signifi cant regional diff erences in dia gnostic effi ciency.

Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients

“…In the Czech Republic the average incidence of breast cancer in the population of women during the period 2005-2010 was 65.9 cases per 100,000, with an average mortality of 16.4. In contrast, in the years 1985-1990 the average incidence was 42.9, with average mortality 19.7 (data retrieved from The Czech National Cancer Registry) (1). As indicated, although the incidence has increased by more than one-third in the respective time periods, mainly due to improved screening programs and diagnostics, conversely, mortality has decreased due to earlier detection and more effective treatment.…”

The Impact of High Protein Nutritional Support on Clinical Outcomes and Treatment Costs of Patients with Colorectal Cancer

“…The CNCR analysis is supported by demographic data and by the Death Records Database. An overview of epidemiology of malignant tumors in the Czech population is available on-line at www.svod.cz [3].…”

“…[4]. Numbers of early dia gnosed cases are generally insufficient, even in the case of highly prevalent cancers such as CRC (only 46.1% of incident cases are dia gnosed at stage I or II, according to recent data in the Czech Republic) [3]. Total mortality in the EU due to CRC is expected to rise from 212,000 deaths per year in 2008 to 248,000 in 2020 [2].…”

Regional Geographic Variations in Kidney Cancer Incidence Rates in European Countries

“…In addition, a few regional reports have revealed intriguing variations in kidney cancer incidence rates within countries [7][8][9][10]. Systematic analyses of regional incidence rates have been sparse and have so far focused on northern Europe, where differences between national rates are moderate [11,12].…”